Drug | Page 228 of 280 | SpiritIndia.com

Health :: Do not unauthorized products for sexual enhancement due to potential health risks

Health Canada is advising consumers not to use the unauthorized natural health products Zimaxx, Actra-Rx, 4Everon, Vigor-25 and Nasutra because they are adulterated with pharmaceutical ingredients that should only be used under medical supervision. The use of these products could pose a serious health risk, especially for patients with existing medical conditions such as heart problems, those who are taking heart medications, or those who may be at risk for strokes.

Health :: FDA Seeks Injunction of Seafood Processor

The Food and Drug Administration (FDA) announced that it is seeking a permanent injunction against Worldwide Fish & Seafood, Inc. (Worldwide Fish), Suzanne Weinstein, its president and owner, and Timothy A. Lauer, its general manager. Worldwide Fish does business as Coastal Seafood, a seafood processor located at 2330 Minnehaha Avenue, in Minneapolis, Minnesota. The firm distributes seafood products to restaurants in Wisconsin, Minnesota, Iowa, and North and South Dakota.

Health :: Agenda Items for the 38th Session of the Codex Committee on Food Hygiene

The Office of the Under Secretary for Food Safety, U.S. Department of Agriculture (USDA) and the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services announced a public meeting to provide information and receive public comments on agenda items and draft U.S. positions for the 38th Session of the Codex Committee on Food Hygiene (CCFH), to be held Dec. 4 – 9, in Houston, Texas.

Health :: Incentive-Based Therapy Improves Outlook For Methamphetamine Abusers

New research suggests that offering methamphetamine abusers an incentive-based behavioral therapy program called contingency management (CM ? also known as Motivational Incentives), along with psychosocial therapy is more effective than psychosocial therapy alone. The study was supported by the National Institute on Drug Abuse (NIDA), National Institutes of Health, and is published in the November 2006 issue of the American Journal of Psychiatry.

Health :: WHO to tackle counterfeit medical products – IMPACT

On 15 November, the World Health Organization (WHO) and its partners will officially launch the first ever International Medical Products Anti-counterfeiting Taskforce (IMPACT) and unveil the global plan to combat counterfeit medical products.

Colorectal Cancer :: Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer

ImClone Systems Incorporated (NASDAQ:IMCL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced results from two randomized Phase III trials of ERBITUX(R) (cetuximab) in patients with metastatic colorectal cancer. These are the first large, randomized studies to examine the impact of ERBITUX treatment on overall survival in colon cancer.

Osteoarthritis :: Prexige in the European Union as a new treatment option for osteoarthritic pain

Novartis announced today that Prexige? (lumiracoxib), an oral selective COX-2 inhibitor anti-inflammatory drug, has been cleared for approval in the European Union as a new treatment option for patients suffering from osteoarthritis. This is the most common form of arthritis and a leading cause of chronic pain[2].

Health Care :: Novartis creates new strategic biomedical R&D center in Shanghai

Novartis announced plans to build an integrated biomedical Research & Development center in Shanghai’s Zhangjiang Hi-Tech Park that will become an integral part of the Group’s global research and development network.

Health :: FDA issues approvable letter for Entereg for POI

GlaxoSmithKline (NYSE: GSK) and Adolor Corporation (Nasdaq: ADLR) announced that the Food and Drug Administration (FDA) has issued a letter stating that the new drug application (NDA) for Entereg (alvimopan 12mg) for the management of post operative ileus (POI) is approvable. The FDA has requested 12-month safety data, including analysis of serious cardiovascular events, from study 014 (767905/014), an ongoing safety study in opioid-induced bowel dysfunction (OBD). The FDA also requested a risk management plan as part of the submission.

Pregnancy :: Rare infections after medically induced abortions likely not drug-related

Since 2000, five women in North America who had medically induced abortions died from toxic shock caused by a Clostridium sordellii infection. This has led some people to question the safety of the combination of the drugs mifepristone and misoprostol frequently used in MIA procedures.